Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a recombinant DNA advisory committee symposium held June 15, 2010

Hildegund C.J. Ertl, John Zaia, Steven A. Rosenberg, Carl H. June, Gianpietro Dotti, Jeffrey Kahn, Laurence J.N. Cooper, Jacqueline Corrigan-Curay, Scott E. Strome

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

T cells that are genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials. Unfortunately, 2 recent deaths in cancer patients treated with CAR T cells have created some uncertainty on how to best mitigate patient risk, while continuing to advance this very promising therapeutic avenue. In order to address these concerns, the Recombinant DNA Advisory Committee (RAC) held a symposium, the objectives of which were to first review the reported treatment-associated toxicities and, second, to discuss methods for improving safety and efficacy. This report highlights the issues raised as part of this discussion, with a specific focus on protocols infusing CAR T cells. Because this was not a consensus conference, the opinions described should not be construed to represent those of any individual RAC member, the RAC as a body, conference participants, the National Institutes of Health, or the U.S. Food and Drug Administration.

Original languageEnglish (US)
Pages (from-to)3175-3181
Number of pages7
JournalCancer research
Volume71
Issue number9
DOIs
StatePublished - May 1 2011

Fingerprint

Recombinant DNA
Advisory Committees
T-Cell Antigen Receptor
Committee Membership
Antigen Receptors
National Institutes of Health (U.S.)
United States Food and Drug Administration
Immunotherapy
Uncertainty
Neoplasms
Clinical Trials
T-Lymphocytes
Safety
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Considerations for the clinical application of chimeric antigen receptor T cells : Observations from a recombinant DNA advisory committee symposium held June 15, 2010. / Ertl, Hildegund C.J.; Zaia, John; Rosenberg, Steven A.; June, Carl H.; Dotti, Gianpietro; Kahn, Jeffrey; Cooper, Laurence J.N.; Corrigan-Curay, Jacqueline; Strome, Scott E.

In: Cancer research, Vol. 71, No. 9, 01.05.2011, p. 3175-3181.

Research output: Contribution to journalArticle

Ertl, HCJ, Zaia, J, Rosenberg, SA, June, CH, Dotti, G, Kahn, J, Cooper, LJN, Corrigan-Curay, J & Strome, SE 2011, 'Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a recombinant DNA advisory committee symposium held June 15, 2010', Cancer research, vol. 71, no. 9, pp. 3175-3181. https://doi.org/10.1158/0008-5472.CAN-10-4035
Ertl, Hildegund C.J. ; Zaia, John ; Rosenberg, Steven A. ; June, Carl H. ; Dotti, Gianpietro ; Kahn, Jeffrey ; Cooper, Laurence J.N. ; Corrigan-Curay, Jacqueline ; Strome, Scott E. / Considerations for the clinical application of chimeric antigen receptor T cells : Observations from a recombinant DNA advisory committee symposium held June 15, 2010. In: Cancer research. 2011 ; Vol. 71, No. 9. pp. 3175-3181.
@article{bac90be2d5d34caea3817b3ddcc01629,
title = "Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a recombinant DNA advisory committee symposium held June 15, 2010",
abstract = "T cells that are genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials. Unfortunately, 2 recent deaths in cancer patients treated with CAR T cells have created some uncertainty on how to best mitigate patient risk, while continuing to advance this very promising therapeutic avenue. In order to address these concerns, the Recombinant DNA Advisory Committee (RAC) held a symposium, the objectives of which were to first review the reported treatment-associated toxicities and, second, to discuss methods for improving safety and efficacy. This report highlights the issues raised as part of this discussion, with a specific focus on protocols infusing CAR T cells. Because this was not a consensus conference, the opinions described should not be construed to represent those of any individual RAC member, the RAC as a body, conference participants, the National Institutes of Health, or the U.S. Food and Drug Administration.",
author = "Ertl, {Hildegund C.J.} and John Zaia and Rosenberg, {Steven A.} and June, {Carl H.} and Gianpietro Dotti and Jeffrey Kahn and Cooper, {Laurence J.N.} and Jacqueline Corrigan-Curay and Strome, {Scott E.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-10-4035",
language = "English (US)",
volume = "71",
pages = "3175--3181",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Considerations for the clinical application of chimeric antigen receptor T cells

T2 - Observations from a recombinant DNA advisory committee symposium held June 15, 2010

AU - Ertl, Hildegund C.J.

AU - Zaia, John

AU - Rosenberg, Steven A.

AU - June, Carl H.

AU - Dotti, Gianpietro

AU - Kahn, Jeffrey

AU - Cooper, Laurence J.N.

AU - Corrigan-Curay, Jacqueline

AU - Strome, Scott E.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - T cells that are genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials. Unfortunately, 2 recent deaths in cancer patients treated with CAR T cells have created some uncertainty on how to best mitigate patient risk, while continuing to advance this very promising therapeutic avenue. In order to address these concerns, the Recombinant DNA Advisory Committee (RAC) held a symposium, the objectives of which were to first review the reported treatment-associated toxicities and, second, to discuss methods for improving safety and efficacy. This report highlights the issues raised as part of this discussion, with a specific focus on protocols infusing CAR T cells. Because this was not a consensus conference, the opinions described should not be construed to represent those of any individual RAC member, the RAC as a body, conference participants, the National Institutes of Health, or the U.S. Food and Drug Administration.

AB - T cells that are genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials. Unfortunately, 2 recent deaths in cancer patients treated with CAR T cells have created some uncertainty on how to best mitigate patient risk, while continuing to advance this very promising therapeutic avenue. In order to address these concerns, the Recombinant DNA Advisory Committee (RAC) held a symposium, the objectives of which were to first review the reported treatment-associated toxicities and, second, to discuss methods for improving safety and efficacy. This report highlights the issues raised as part of this discussion, with a specific focus on protocols infusing CAR T cells. Because this was not a consensus conference, the opinions described should not be construed to represent those of any individual RAC member, the RAC as a body, conference participants, the National Institutes of Health, or the U.S. Food and Drug Administration.

UR - http://www.scopus.com/inward/record.url?scp=79955512733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955512733&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-4035

DO - 10.1158/0008-5472.CAN-10-4035

M3 - Article

C2 - 21531763

AN - SCOPUS:79955512733

VL - 71

SP - 3175

EP - 3181

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -